World to Benefit from Rapid Implementation of Artificial Intelligence in Neurology Devices: Fact.MR Study

As per a new report by Fact.MR, a market research and competitive intelligence provider, the global neurology devices market is anticipated to reach a valuation of US$ 13 billion by 2027.

The prevalence of several neurological conditions as well as cerebrovascular disorders such as stroke, migraine, and headache is increasing across the world, which is driving up demand for neurology devices. Growing preference for minimally-invasive procedures and ongoing innovations in neurology equipment are also increasing market value.

With the support of non-invasive, image-guided neurology technologies, neurovascular issues such as tumors, cavernous malformations, and stroke are addressed. The market for neurology devices is expanding as a result of many key variables, including an increase in head traumas, high rates of stress in young people, an increase in the geriatric population, and a large patient base.

Rising patient awareness regarding the availability of treatment and reimbursement for neurovascular illnesses, particularly in emerging countries, are factors that will accelerate market expansion.

The use of artificial intelligence (AI) in neurology is anticipated to support market expansion. Computer-aided diagnosis (CAD) systems that employ AI and advanced signal processing methods can assist physicians in analyzing and understanding physiological signals and images more accurately.

Key Takeaways from Market Study

  • Worldwide demand for neurology devices is expected to rise at a CAGR of 6.2% through 2027.
  • The global neurology devices market is currently valued at US$ 9.6 billion.
  • The market in Canada is anticipated to expand at a CAGR of 5.5% over the forecast period (2022-2027).
  • Sales of interventional neurology devices are predicted to increase at a CAGR of 6.4% from 2022 to 2027.
  • The market in Germany is set to increase at a CAGR of 4% through 2027.

Market expansion is attributed to growing investments by key manufacturers of medical devices, increasing efforts by public & private institutions to improve and execute payment procedures for treating neurovascular disorders, and extensive research & development in neurotherapy,” says a Fact.MR analyst

Winning Strategy

Top companies are engaged in the introduction of magnetic stimulation technology as a result of innovations in neurostimulation and neuromodulation techniques. Key market players are collaborating with research organizations to increase their presence and contribute to the creation of modern as well as safe processes.

For instance,

  • In April 2022, an updated version of Abbott’s NeuroSphere myPath digital health app was released. Abbott neurostimulation devices are used by patients to treat their chronic pain, and the functionality of the app improved to help doctors better monitor their patients during this process.

These insights are based on a report on Neurology Diagnostics Devices Market by Fact.MR.

 

SourceFACT.MR

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”